The highly used cancer imaging technique, [18F]FDG-PET, is based on the increased glucose metabolic activity in tumors. However, since there are other biological processes that exhibit increased metabolic activity, in particular inflammation, this methodology is prone to non-specificity for cancer. Herein we describe the development of a novel nanoparticle-based approach, utilizes Glucose-Functionalized Gold Nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our method has demonstrated specific tumor targeting and has successfully differentiated between cancer and inflammation in a combined tumor-inflammation mouse model, due to dissimilarities in vasculatures in different pathologic conditions. This novel approach provides new capabilities in cancer imaging, and can be applicable to a wide range of cancers.
|Title of host publication||Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV|
|Editors||Dan V. Nicolau, Dror Fixler, Alexander N. Cartwright|
|State||Published - 2017|
|Event||Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV 2017 - San Francisco, United States|
Duration: 30 Jan 2017 → 1 Feb 2017
|Name||Progress in Biomedical Optics and Imaging - Proceedings of SPIE|
|Conference||Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV 2017|
|Period||30/01/17 → 1/02/17|
Bibliographical noteFunding Information:
This work was partially supported by the Research and Development Chief Scientist Kamin grant (49544), by the Israel Cancer Research Fund (ICRF), by the Israel Science Foundation grant (749/14), and by the doctoral scholarship for applicable and scientific engineering research, granted to Tamar Dreifuss and Oshra Betzer by the Ministry of Science, Technology & Space, Israel.
© 2017 SPIE.
- Gold nanoparticles
- Metabolic-based imaging